Gene Logic Adds Lilly To Its Drug Rescue Roster
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will reconsider drug candidates that were “discontinued or de-prioritized” for non-safety reasons and could even license them if Lilly opts out.
You may also be interested in...
Abbott Joins Gene Logic’s Stable Of Pharma Partners
Abbott could pay Gene Logic as much as $100 million in milestones for each drug candidate that is eventually marketed, firm tells “The Pink Sheet” DAILY.
Abbott Joins Gene Logic’s Stable Of Pharma Partners
Abbott could pay Gene Logic as much as $100 million in milestones for each drug candidate that is eventually marketed, firm tells “The Pink Sheet” DAILY.
Pfizer Aims To Revive Drug Candidates Through Gene Logic Agreement
Gene Logic will screen unapproved compounds for possible new indications with the goal of returning them to clinical development.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: